These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 22163004)
1. Correlation of inter-locus polyglutamine toxicity with CAG•CTG triplet repeat expandability and flanking genomic DNA GC content. Nestor CE; Monckton DG PLoS One; 2011; 6(12):e28260. PubMed ID: 22163004 [TBL] [Abstract][Full Text] [Related]
2. Age-, tissue- and length-dependent bidirectional somatic CAG•CTG repeat instability in an allelic series of R6/2 Huntington disease mice. Larson E; Fyfe I; Morton AJ; Monckton DG Neurobiol Dis; 2015 Apr; 76():98-111. PubMed ID: 25662336 [TBL] [Abstract][Full Text] [Related]
3. The CAG/polyglutamine tract diseases: gene products and molecular pathogenesis. Koshy BT; Zoghbi HY Brain Pathol; 1997 Jul; 7(3):927-42. PubMed ID: 9217976 [TBL] [Abstract][Full Text] [Related]
4. Cis-acting modifiers of expanded CAG/CTG triplet repeat expandability: associations with flanking GC content and proximity to CpG islands. Brock GJ; Anderson NH; Monckton DG Hum Mol Genet; 1999 Jun; 8(6):1061-7. PubMed ID: 10332038 [TBL] [Abstract][Full Text] [Related]
5. Spinocerebellar ataxia type 2: polyQ repeat variation in the CACNA1A calcium channel modifies age of onset. Pulst SM; Santos N; Wang D; Yang H; Huynh D; Velazquez L; Figueroa KP Brain; 2005 Oct; 128(Pt 10):2297-303. PubMed ID: 16000334 [TBL] [Abstract][Full Text] [Related]
6. Instability of expanded CAG/CAA repeats in spinocerebellar ataxia type 17. Gao R; Matsuura T; Coolbaugh M; Zühlke C; Nakamura K; Rasmussen A; Siciliano MJ; Ashizawa T; Lin X Eur J Hum Genet; 2008 Feb; 16(2):215-22. PubMed ID: 18043721 [TBL] [Abstract][Full Text] [Related]
7. The New Face of Dynamic Mutation-The CAA [CAG]n CAA CAG Motif as a Mutable Unit in the Hoffman-Zacharska D; Sulek A Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125760 [TBL] [Abstract][Full Text] [Related]
8. The role of interruptions in polyQ in the pathology of SCA1. Menon RP; Nethisinghe S; Faggiano S; Vannocci T; Rezaei H; Pemble S; Sweeney MG; Wood NW; Davis MB; Pastore A; Giunti P PLoS Genet; 2013; 9(7):e1003648. PubMed ID: 23935513 [TBL] [Abstract][Full Text] [Related]
9. Preclinical Nanomedicines for Polyglutamine-Based Neurodegenerative Diseases. Lee LKC; Leong LI; Liu Y; Luo M; Chan HYE; Choi CHJ Mol Pharm; 2021 Feb; 18(2):610-626. PubMed ID: 32584043 [TBL] [Abstract][Full Text] [Related]
10. The CAG-polyglutamine repeat diseases: a clinical, molecular, genetic, and pathophysiologic nosology. Stoyas CA; La Spada AR Handb Clin Neurol; 2018; 147():143-170. PubMed ID: 29325609 [TBL] [Abstract][Full Text] [Related]
11. HD and SCA1: Tales from two 30-year journeys since gene discovery. Thompson LM; Orr HT Neuron; 2023 Nov; 111(22):3517-3530. PubMed ID: 37863037 [TBL] [Abstract][Full Text] [Related]
12. AAV-Mediated CAG-Targeting Selectively Reduces Polyglutamine-Expanded Protein and Attenuates Disease Phenotypes in a Spinocerebellar Ataxia Mouse Model. Niewiadomska-Cimicka A; Fievet L; Surdyka M; Jesion E; Keime C; Singer E; Eisenmann A; Kalinowska-Poska Z; Nguyen HHP; Fiszer A; Figiel M; Trottier Y Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673939 [TBL] [Abstract][Full Text] [Related]
13. Frequency and distribution of polyQ disease intermediate-length repeat alleles in healthy Italian population. Mongelli A; Magri S; Salvatore E; Rizzo E; De Rosa A; Fico T; Gatti M; Gellera C; Taroni F; Mariotti C; Nanetti L Neurol Sci; 2020 Jun; 41(6):1475-1482. PubMed ID: 31940111 [TBL] [Abstract][Full Text] [Related]
14. Possible reduced penetrance of expansion of 44 to 47 CAG/CAA repeats in the TATA-binding protein gene in spinocerebellar ataxia type 17. Oda M; Maruyama H; Komure O; Morino H; Terasawa H; Izumi Y; Imamura T; Yasuda M; Ichikawa K; Ogawa M; Matsumoto M; Kawakami H Arch Neurol; 2004 Feb; 61(2):209-12. PubMed ID: 14967767 [TBL] [Abstract][Full Text] [Related]
16. A peptidylic inhibitor for neutralizing expanded Zhang Q; Chen ZS; An Y; Liu H; Hou Y; Li W; Lau KF; Koon AC; Ngo JCK; Chan HYE RNA; 2018 Apr; 24(4):486-498. PubMed ID: 29295891 [TBL] [Abstract][Full Text] [Related]
17. Polyglutamine (PolyQ) diseases: genetics to treatments. Fan HC; Ho LI; Chi CS; Chen SJ; Peng GS; Chan TM; Lin SZ; Harn HJ Cell Transplant; 2014; 23(4-5):441-58. PubMed ID: 24816443 [TBL] [Abstract][Full Text] [Related]
18. PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. Yu Z; Zhu Y; Chen-Plotkin AS; Clay-Falcone D; McCluskey L; Elman L; Kalb RG; Trojanowski JQ; Lee VM; Van Deerlin VM; Gitler AD; Bonini NM PLoS One; 2011 Mar; 6(3):e17951. PubMed ID: 21479228 [TBL] [Abstract][Full Text] [Related]
19. Toxicity of pathogenic ataxin-2 in Drosophila shows dependence on a pure CAG repeat sequence. McGurk L; Rifai OM; Shcherbakova O; Perlegos AE; Byrns CN; Carranza FR; Zhou HW; Kim HJ; Zhu Y; Bonini NM Hum Mol Genet; 2021 Sep; 30(19):1797-1810. PubMed ID: 34077532 [TBL] [Abstract][Full Text] [Related]
20. The unstable trinucleotide repeat story of major psychosis. Vincent JB; Paterson AD; Strong E; Petronis A; Kennedy JL Am J Med Genet; 2000; 97(1):77-97. PubMed ID: 10813808 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]